Study of the Safety Pharmacokinetics Pharmacodynamics and Preliminary

Recruiting

12 years - 99 years

All

Phase 1

10 participants needed

1 Location

Brief description of study

The primary purpose of this study is to assess the safety and tolerability of an Investigational drug in patients with eligible advanced solid tumors, determine the maximum tolerated dose (MTD) and assess preliminary anti-tumor activity.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: Advanced Solid Tumor
Age: 12 years - 99 years
Gender: All

Male or female and ≥12 years-of-age, advanced or metastatic resistant or refractory solid tumors.

Updated on 04 Aug 2024. Study ID: 849282

Find a site

Your Information has been sent successfully.

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.

Would you like to be notified about other trials? Sign up for Patient Notification Services.

Send a message

Enter your contact details to connect with study team

Primary Contact

First name*

Last name*

Email*

Phone number*

Preferred way of contact

Race

Ethnicity

Are you Healthy Volunteer

Are you comfortable with the informed consent process?

Yes

Other language

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

Study of the Safety Pharmacokinetics Pharmacodynamics and Preliminary Clinical Activity of RP-6306 in Patients with Advanced Solid Tumors (MYTHIC Study)

Brief description of study

Eligibility of study

Find a site

Interested in the study